ARUN MUNJAL: Open Payments
NPI 1730150814 · SMYRNA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,914 in 72 payments from 13 companies in 2025. Trend: 2023 $1,812 · 2024 $1,626 · 2025 $1,914
Food & beverage: $1,909Education: $5
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $372 |
| Tris Pharma Inc | 2 | $236 |
| Axsome Therapeutics, Inc. | 7 | $187 |
| Neurocrine BioSciences, Inc. | 6 | $175 |
| Janssen Pharmaceuticals, Inc | 8 | $168 |
| E.R. Squibb & Sons, L.L.C. | 4 | $161 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $158 |
| Otsuka America Pharmaceutical, Inc. | 7 | $135 |
| Corium, LLC | 8 | $118 |
| ABBVIE INC. | 4 | $76 |
Products named: Dyanavel XR, UZEDY, Auvelity, INGREZZA, COBENFY, CAPLYTA, AUSTEDO XR, SPRAVATO.
Industry payments across GA — which companies pay providers there.
